Toll Free: 1-888-928-9744

Hemorrhagic Shock - Pipeline Review, H1 2016

Published: Mar 22, 2016 | Pages: 37 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hemorrhagic Shock - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Hemorrhagic Shock - Pipeline Review, H1 2016', provides an overview of the Hemorrhagic Shock pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Hemorrhagic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hemorrhagic Shock and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hemorrhagic Shock
- The report reviews pipeline therapeutics for Hemorrhagic Shock by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Hemorrhagic Shock therapeutics and enlists all their major and minor projects
- The report assesses Hemorrhagic Shock therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Hemorrhagic Shock

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Hemorrhagic Shock
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hemorrhagic Shock pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Hemorrhagic Shock Overview 6 Therapeutics Development 7 Pipeline Products for Hemorrhagic Shock - Overview 7 Hemorrhagic Shock - Therapeutics under Development by Companies 8 Hemorrhagic Shock - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Hemorrhagic Shock - Products under Development by Companies 11 Hemorrhagic Shock - Companies Involved in Therapeutics Development 12 Biomedica Management Corporation 12 SynZyme Technologies, LLC 13 Hemorrhagic Shock - Therapeutics Assessment 14 Assessment by Monotherapy Products 14 Assessment by Target 15 Assessment by Mechanism of Action 17 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Drug Profiles 23 AM/AMBP-1 - Drug Profile 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 HemoZyme - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Neutrolide - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 NVX-408 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Recombinant Protein for Sepsis, Inflammatory Bowel Disease, Acute Kidney Injury, Acute Radiation Syndrome and Ischemic Organ Injury - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Synthetic Peptide to Inhibit TREM-1 for Cancer, Sepsis, Rheumatoid Arthritis and Hemorrhagic Shock - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Hemorrhagic Shock - Recent Pipeline Updates 33 Hemorrhagic Shock - Dormant Projects 34 Hemorrhagic Shock - Discontinued Products 35 Appendix 36 Methodology 36 Coverage 36 Secondary Research 36 Primary Research 36 Expert Panel Validation 36 Contact Us 36 Disclaimer 37
List of Tables
Number of Products under Development for Hemorrhagic Shock, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 9 Comparative Analysis by Early Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Hemorrhagic Shock - Pipeline by Biomedica Management Corporation, H1 2016 12 Hemorrhagic Shock - Pipeline by SynZyme Technologies, LLC, H1 2016 13 Assessment by Monotherapy Products, H1 2016 14 Number of Products by Stage and Target, H1 2016 16 Number of Products by Stage and Mechanism of Action, H1 2016 18 Number of Products by Stage and Route of Administration, H1 2016 20 Number of Products by Stage and Molecule Type, H1 2016 22 Hemorrhagic Shock Therapeutics - Recent Pipeline Updates, H1 2016 33 Hemorrhagic Shock - Dormant Projects, H1 2016 34 Hemorrhagic Shock - Discontinued Products, H1 2016 35


List of Figures
Number of Products under Development for Hemorrhagic Shock, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Early Stage Products, H1 2016 10 Assessment by Monotherapy Products, H1 2016 14 Number of Products by Targets, H1 2016 15 Number of Products by Stage and Targets, H1 2016 15 Number of Products by Mechanism of Actions, H1 2016 17 Number of Products by Stage and Mechanism of Actions, H1 2016 17 Number of Products by Routes of Administration, H1 2016 19 Number of Products by Stage and Routes of Administration, H1 2016 19 Number of Products by Molecule Types, H1 2016 21 Number of Products by Stage and Molecule Types, H1 2016 21

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected to

Read More...

Global outsourced customer care services market is projected to reach USD 84.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Swelling need for interaction through non-voice channels is estimated to boost global demand over t

Read More...

Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliab

Read More...

Global commercial drone market size is estimated to reach USD 2,069.6 million by 2022, as per a new research report by Radiant Insights, Inc. Increasing application of these machines in various industry sectors such as military, agriculture and energ

Read More...

Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the gl

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify